DigiDiab Pilot: Impact Study Hospital
Recruiting · NCT06605872 · Observational (researchers observe without assigning treatment) · Lead sponsor: Medical University of Graz
View the official record on ClinicalTrials.gov →Interventions studied
Diabetes TreatmentGlucoTab
What this trial is about
GlucoTab is an innovative workflow and decision support tool for standardised diabetes management by healthcare professionals which provides automated and personalised dosage recommendations for different insulin therapy regimens.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- informed consent obtained after being advised of the nature of the study
- a documented history of type 2 diabetes prior to inclusion or new-onset hyperglycaemia which requires s.c. insulin therapy during hospital stay
- admission to either surgical or internal medicine ward
- an expected length of hospital stay for at least 48 hours after enrolment
Exclusion criteria
- type 1 diabetes mellitus
- intravenous insulin therapy
- hyperglycaemic episodes (ketoacidosis, hyperosmolar state) if they require intravenous insulin therapy
- continuous subcutaneous insulin infusion
- gestational diabetes or pregnancy
- known or suspected allergy to insulin
- total parenteral nutrition
- any mental condition rendering the patient incapable of giving his/her consent
- any disease or condition which according to the investigator or treating physician would interfere with the trial or the safety of the patient
- Inclusion and exclusion criteria will be the same as above for the retrospective CG with the exception of:
- period of time will be from September 2022 to September 2023
- no informed consent will be obtained from the retrospective CG
Where it is running
1 location listed.
- Hospital Universitari Joan XXIII de Tarragona - Tarragona, Spain